Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058266 · ClinicalTrials.gov registry record · Phase 2
Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00058266 is a Phase 2 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 36 participants.
The verdict
NCT00058266, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Genistein may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of genistein in treating patients with localized prostate cancer who are planning to undergo radical prostatectomy.
Interventions
- PROCEDURE conventional surgery
- DIETARY_SUPPLEMENT genistein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2002-12 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058266
The ClinicalTrials.gov registry entry for NCT00058266 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which conventional surgery is the first listed.
NCT00058266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00058266 about?
NCT00058266 is a clinical study titled "Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy". RATIONALE: Genistein may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of genistein in treating patients with localized prostate cancer who are planning to undergo radical prostatectomy.
What is the current status of trial NCT00058266?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2002-12. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00058266?
The interventions under investigation include: conventional surgery (PROCEDURE), genistein (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00058266?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.